[Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause].
Triptans, 5-HT1B/1D agonists used in migraine treatment, are rarely involved in serious coronary events due to vasospasm. 5 HT1 receptors mediate vasodilation and vasoconstriction of coronary arteries. Reports of serious coronary events mainly concern patients with known risk factors for coronary artery disease. It is prudent to obtain a thorough medical history before treatment with a triptan is started. If chest pain occurs, the possibility of coronary ischemia should be investigated. Stroke, a known complication to migraine, has also been reported in patients treated with triptans, but available data do not suggest that triptans, when correctly used, greatly increase the risk.
Klinisk farmakologi, biverkningssektionen, Läkemedelsverket, Uppsala. karin.hedenmalm@mpa.se
K
K
Hedenmalm
D000075202:Contraindications; D003327:Coronary Disease / Q000139:chemically induced*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000139:chemically induced; D018570:Risk Assessment; D012307:Risk Factors; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D020521:Stroke / Q000139:chemically induced; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects*
D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan